Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939568 | 1.00 | ELANE (0.31) | ELANE | |
| SCHEMBL9904570 | 0.90 | — | — | |
| SCHEMBL9905017 | 0.89 | AR (0.37) | — | |
| SCHEMBL30939540 | 0.89 | AR (0.37) | — | |
| SCHEMBL21857675 | 0.88 | — | — | |
| SCHEMBL19853468 | 0.86 | — | — | |
| SCHEMBL30939564 | 0.86 | MMP13 (0.32) | ELANE | |
| SCHEMBL9923854 | 0.86 | MMP13 (0.32) | ELANE | |
| SCHEMBL18987269 | 0.83 | — | — | |
| SCHEMBL9904667 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | claimed |
| US-10835534-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-11-17 | — | — | US | claimed |
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | claimed |
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2019-01-03 | — | — | US | claimed |
| US-20190000849-A1 | NOVEL COMPOUNDS | AUTIFONY THERAPEUTICS LIMITED | 2019-01-03 | — | — | US | claimed |
| EP-3386506-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | Autifony Therapeutics Limited (GB) | 2018-10-17 | — | — | EP | claimed |
| US-10098881-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-10-16 | — | — | US | claimed |
| US-20180036308-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2018-02-08 | — | — | US | claimed |
| WO-2017098254-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2017-06-15 | — | — | WO | claimed |
| US-20160317537-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2016-11-03 | — | — | US | claimed |
| EP-2788339-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2016-03-09 | — | — | EP | claimed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | claimed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | claimed |
| EP-2788339-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | claimed |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-118267386-A | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000848-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | ELANE 3621/4885 |
| US-20190000849-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ELANE 3693/4885 |
| US-10835534-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ELANE 3231/4885 |
| US-20160317537-A1 | NOVEL COMPOUNDS | KCNN3, KCNN2, KCNN1 | ELANE 3502/4885 |
| US-10555945-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | ELANE 3231/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | ELANE 3602/4885 |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | ELANE 3666/4885 |
| US-20140323508-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | ELANE 3693/4885 |
| US-10098881-B2 | Compounds | FANCI, CYFIP1, ZFX | ELANE 878/4885 |
| US-20180036308-A1 | NOVEL COMPOUNDS | CYFIP1, CYFIP2, ZFX | ELANE 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.